Connor Clark & Lunn Investment Management Ltd. Reduces Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Connor Clark & Lunn Investment Management Ltd. lowered its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – ...
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
Partex's platform will provide comprehensive analyses, including target identification, indication expansion, and molecular profiling, ultimately accelerating the process of bringing innovative ...
EverSource Wealth Advisors LLC Sells 6,469 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
EverSource Wealth Advisors LLC lowered its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 91.1% in the ...
Yahoo Finance9d
NB Renaissance Nears Deal for CVC-Backed Genetic
NB Renaissance sees pharmaceutical assets as core to its investment strategy. In 2022, it partnered with Ardian to acquire a majority stake in Italy’s Neopharmed Gentili, which specializes in ...
Knight Therapeutics to Acquire Paladin Pharma for C$120M
Knight Therapeutics has agreed to acquire generics and specialty branded pharmaceutical company Paladin Pharma for 120 million Canadian dollars ($83.1 million).
Recursion Pharmaceuticals's Options: A Look at What the Big Money is Thinking
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating ...
Morningstar4d
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
and potentially repositioning promising bio-pharmaceutical assets.” Partex's platform will provide comprehensive analyses, including target identification, indication expansion, and molecular ...